Basit öğe kaydını göster

Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

dc.contributor.authorPittock, S.
dc.contributor.authorBerthele, A.
dc.contributor.authorFujihara, K.
dc.contributor.authorKim, H. J.
dc.contributor.authorLevy, M.
dc.contributor.authorPalace, J.
dc.contributor.authorWingerchuk, D. M.
dc.date.accessioned2020-06-21T12:26:00Z
dc.date.available2020-06-21T12:26:00Z
dc.date.issued2019
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10621
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.descriptionWOS: 000485303101161en_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipAlexion PharmaceuticalsFukuda Foundation for Medical TechnologyKayamori FoundationKayamori Foundation of Informational Science AdvancementSENSHIN Medical Research FoundationSasagawa Scientific Research GrantMukai Science and Technology Foundationen_US
dc.description.sponsorshipThis trial was supported by Alexion Pharmaceuticals. Dr Pittock reports grants, personal fees and non-financial support from Alexion Pharmaceuticals; grants from the Autoimmune Encephalitis Alliance and Grifols; and grants, personal fees, non-financial support and other from MedImmune, Inc. Dr Pittock has a patent # 9,891,219 (Application # 12-573942) "Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual that is Aquaporin-4 (AQP4)-IgG Autoantibody Positive".; Dr Palace is partly funded by highly specialized services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and fees for advisory from Abide, Alexion, ARGENX, Bayer Schering, Biogen Idec, Chugai Pharma, EuroImmun, Genzyme, MedDay, MedImmune, Merck Serono, Novartis, Roche and Teva, and grants from Abide, Bayer Schering, Biogen Idec, Merck Serono, Novartis and Teva. She has received grants from EDEN, GMSI, the Guthy-Jackson Foundation, the John Fell Fund, the MRC, the MS Society, NIHR and Oxford Health Services Research Committee for research studies.; Dr Wingerchuk reports grants from Alexion Pharmaceuticals during the conduct of the study; and personal fees from Biogen, BrainStorm Therapeutics, Caladrius, Celgene, MedImmune, Novartis and ONO Pharmaceutical.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSubgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume25en_US
dc.identifier.startpage289en_US
dc.identifier.endpage290en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster